A Piece in the Puzzle of Personalized Medicine
暂无分享,去创建一个
[1] M Schwab,et al. UDP‐Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In Vivo , 2010, Clinical pharmacology and therapeutics.
[2] S. Ghosh,et al. Utility of Adiponectin as a Biomarker Predictive of Glycemic Efficacy Is Demonstrated by Collaborative Pooling of Data From Clinical Trials Conducted by Multiple Sponsors , 2009, Clinical pharmacology and therapeutics.
[3] K. Iwasaki,et al. Pretransplant Pharmacodynamic Analysis of Immunosuppressive Agents Using CFSE‐Based T‐Cell Proliferation Assay , 2009, Clinical pharmacology and therapeutics.
[4] M. Imamura,et al. Successful hepatitis B vaccination in liver transplant recipients with donor‐specific hyporesponsiveness , 2009, Transplant international : official journal of the European Society for Organ Transplantation.
[5] M. Daly,et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.
[6] S. Brouard,et al. Can immune monitoring help to minimize immunosuppression in kidney transplantation? , 2009, Transplant international : official journal of the European Society for Organ Transplantation.
[7] J. Chapman,et al. Individualization of immunosuppression: concepts and rationale , 2008, Current opinion in organ transplantation.
[8] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.
[9] G. Boden,et al. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[10] M. Ashiya,et al. Non-insulin therapies for type 2 diabetes , 2007, Nature Reviews Drug Discovery.
[11] R. Krauss,et al. Pharmacogenomics of statin response , 2007, Current opinion in lipidology.
[12] T. Hirano. Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine. , 2007, International immunopharmacology.
[13] 田中 友加. Low incidence of acute rejection after living-donor liver transplantation : immunologic analyses by mixed lymphocyte reaction using a carboxyfluorescein diacetate succinimidyl ester labeling technique , 2006 .
[14] T. Asahara,et al. Low Incidence of Acute Rejection after Living-Donor Liver Transplantation: Immunologic Analyses by Mixed Lymphocyte Reaction using a Carboxyfluorescein Diacetate Succinimidyl Ester Labeling Technique , 2005, Transplantation.
[15] Richard Platt,et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.
[16] T. Asahara,et al. Multiparameter Flow Cytometric Approach for Simultaneous Evaluation of Proliferation and Cytokine‐Secreting Activity in T Cells Responding to Allo‐stimulation , 2004, Immunological investigations.
[17] N. Lameire,et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[18] H. Lennernäs. Clinical Pharmacokinetics of Atorvastatin , 2003, Clinical pharmacokinetics.
[19] P. Neuvonen,et al. Effect of itraconazole on the pharmacokinetics of atorvastatin , 1998, Clinical pharmacology and therapeutics.
[20] H. Gudmundsdottir,et al. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. , 1997, The Journal of clinical investigation.
[21] D. Turner,et al. Fluorescent labeling of dissociated fetal cells for tissue culture , 1992, Journal of Neuroscience Methods.
[22] C. Orosz,et al. SIZE OF THE DONOR‐REACTIVE CTL POOL DETERMINED BY LIMITING DILUTION ANALYSIS IN SPONGE MATRIX ALLOGRAFTS1 , 1986, Transplantation.